These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21224537)

  • 21. Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.
    Tahara M; Shirao K; Boku N; Yamaguchi K; Komatsu Y; Inaba Y; Arai T; Mizunuma N; Satoh T; Takiuchi H; Nishina T; Sakata Y
    Jpn J Clin Oncol; 2008 Nov; 38(11):762-9. PubMed ID: 18836202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
    Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
    Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome.
    Vincenzi B; Santini D; Galluzzo S; Russo A; Fulfaro F; Silletta M; Battistoni F; Rocci L; Zobel BB; Adamo V; Dicuonzo G; Tonini G
    Clin Cancer Res; 2008 Jul; 14(13):4219-24. PubMed ID: 18594003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cetuximab].
    Takiuchi H
    Gan To Kagaku Ryoho; 2007 Aug; 34(8):1192-5. PubMed ID: 17687200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.
    Scartozzi M; Mandolesi A; Giampieri R; Pierantoni C; Loupakis F; Zaniboni A; Galizia E; Giustini L; Silva RR; Bisonni R; Berardi R; Biagetti S; Menzo S; Falcone A; Bearzi I; Cascinu S
    Int J Cancer; 2010 Oct; 127(8):1941-7. PubMed ID: 20099280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan.
    Vincenzi B; Santini D; Russo A; Gavasci M; Battistoni F; Dicuonzo G; Rocci L; Rosaria VM; Gebbia N; Tonini G
    Pharmacogenomics; 2007 Apr; 8(4):319-27. PubMed ID: 17391070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EGFR antibodies in colorectal cancer: where do they belong?
    Grothey A
    J Clin Oncol; 2010 Nov; 28(31):4668-70. PubMed ID: 20921457
    [No Abstract]   [Full Text] [Related]  

  • 28. The price tag on progress--chemotherapy for colorectal cancer.
    Schrag D
    N Engl J Med; 2004 Jul; 351(4):317-9. PubMed ID: 15269308
    [No Abstract]   [Full Text] [Related]  

  • 29. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions.
    Saif MW; Kaley K; Chu E; Copur MS
    Clin Colorectal Cancer; 2010 Dec; 9(5):315-8. PubMed ID: 21208847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-line single-agent cetuximab in patients with advanced colorectal cancer.
    Pessino A; Artale S; Sciallero S; Guglielmi A; Fornarini G; Andreotti IC; Mammoliti S; Comandini D; Caprioni F; Bennicelli E; Andretta V; Siena S; Sobrero A
    Ann Oncol; 2008 Apr; 19(4):711-6. PubMed ID: 18073221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KRAS status predicts response to cetuximab for metastatic colorectal cancer.
    McBride D
    ONS Connect; 2008 Aug; 23(8):25. PubMed ID: 18767573
    [No Abstract]   [Full Text] [Related]  

  • 32. Cetuximab efficacy in patients treated routinely in university hospitals.
    Bachet JB; Afchain P; Fermanian C; Bouchahda M; Mitry E; Landi B; André T; Lièvre A; Louvet C; Aegerter P; Levi F; Rougier P
    Gastroenterol Clin Biol; 2007 Nov; 31(11):941-9. PubMed ID: 18166882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: how much does it cost? A retrospecive economic assessment from a single-center experience.
    Giuliani J; Indelli M; Marzola M; Raisi E; Frassoldati A
    Tumori; 2012; 98(4):408-12. PubMed ID: 23052154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A case of rectal cancer with lung metastases responding to cetuximab].
    Kawai H; Uetake H; Kobayashi H; Enomoto M; Higuchi T; Yasuno M; Iida S; Ishikawa T; Sugihara K
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):2152-4. PubMed ID: 20037353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer.
    Personeni N; Hendlisz A; Gallez J; Galdon MG; Larsimont D; Van Laethem JL; Nagy N; Barette M; Paesmans M; Cardoso F; Bleiberg H
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S59-62. PubMed ID: 16399434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cetuximab and irinotecan for the treatment of metastatic colorectal cancer--pilot results from Masaryk Memorial Cancer Institute].
    Nēmecek R; Kocáková I; Kocák I; Svoboda M; Lakomý R; Poprach A; Vyskocil J; Vyzula R
    Klin Onkol; 2009; 22(1):27-33. PubMed ID: 19534437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Our experience of the treatment with XELOX±Bevacizumab for unresectable advanced colorectal cancer].
    Kashiwagi S; Maeda K; Fuyuhiro Y; Nagahara H; Kimura K; Amano R; Noda E; Kubo N; Tanaka H; Muguruma K; Yashiro M; Yamada N; Nakata B; Ohira M; Ishikawa T; Hirakawa K
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):1936-8. PubMed ID: 22202244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS.
    Shitara K; Yokota T; Takahari D; Shibata T; Ura T; Komatsu Y; Yuki S; Yoshida M; Takiuchi H; Utsunomiya S; Yatabe Y; Muro K
    Jpn J Clin Oncol; 2010 Jul; 40(7):699-701. PubMed ID: 20304778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication.
    Siena S; Glynne-Jones R; Adenis A; Thaler J; Preusser P; Aguilar EA; Aapro MS; Loos AH; Esser R; Wilke H
    Cancer; 2010 Apr; 116(7):1827-37. PubMed ID: 20143444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.